This slowing of motility, ranging from mild constipation to severe gastroparesis, results in gastrointestinal stasis
Investigation of the Interaction Between Angiotensin-Converting Enzyme (ACE) and ACE-Inhibitory Tripeptide from Casein
The maintenance phase challenge What happens when you stop: Appetite returns (gradually over weeks) Need to rely on habits built during weight loss Risk of regaining weight if not careful Success factors: How long you maintained at goal weight while on peptides Habits built during weight loss phase Continued protein intake and training Realistic expectations (some people maintain perfectly, others regain some) Tapering off GLP-1s Don't quit cold turkey: Gradually reduce dose over 4-8 weeks Example: 2.4mg 1.7mg 1mg 0.5mg 0.25mg stop This allows appetite to return gradually Gives you time to adjust habits While tapering: Monitor weight weekly If starting to regain, slow taper Maintain protein intake religiously Keep training consistent Long-term maintenance options Option 1: Cruise dose Stay on low dose GLP-1 indefinitely (0.25-0.5mg weekly) Maintains some appetite suppression Prevents regain Safer long-term than high doses Option 2: Cycle on/off 3-4 months on, 1-2 months off Return to peptides if weight creeps up 5+ pounds Allows body breaks from medication Option 3: Switch to sustainable peptides Transition from GLP-1s to CJC-1295/Ipamorelin Maintains metabolic benefits Supports muscle and recovery No appetite suppression (must rely on habits) Learn how to structure long-term protocols in our peptide cycle planning guide
This suggests a potential link between the drug and the condition, at least in patients with type 2 diabetes
He just had a sort of a nagging suspicion that it's all corrupt and crooked
Ipamorelin is a ghrelin mimetic (a growth hormone secretagogue): it acts on a separate receptor to add to the same GH pulse
